[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VivaVision Biotech, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100612896","phase-1-a-phase-i-study-evaluating-the-safety-tolerability-and-pharmacokinetics-of-vvn432-nasal-spray-100612896",false,"NCT07259538","A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray","A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray in Healthy Chinese Adult Subjects and Patients With Chronic Rhinosinusitis.","Inclusion Criteria:\n\nPart 1:\n\n* Healthy male or female subjects aged 18 to 55 years old (inclusive);\n* Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; body mass index (BMI) within the range of 18.5 to 28.0 kg\u002Fm2 (inclusive);\n* No clinically significant abnormalities at screening or baseline.\n\nPart 2:\n\n* Male or female patients aged 18 to 55 years old (inclusive);\n* Clinically confirmed diagnosis of chronic rhinosinusitis with or without nasal polyps;\n* Presence of the following symptoms for \\>4 weeks before screening: nasal obstruction, mucous or mucopurulent rhinorrhea, facial pain\u002Fpressure, and reduced or lost sense of smell;\n* Modified Lund-Kennedy (MLK) score ≥ 2 in each nostril by nasal endoscopy;\n* Lund-Mackay score (LMK) ≥ 2 in each nostril by CT scan;\n* Nasal Construction Score (NCS) ≥ 2.\n\nExclusion Criteria:\n\nPart 1:\n\n* Known hypersensitivity or contraindications to the study drug or its components;\n* History or current conditions that affect the safety or absorption of the investigational drug;\n* History of drug abuse or drug dependence;\n* Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;\n* If female, is pregnant or lactating, or intends to become pregnant during the study period.\n\nPart 2:\n\n* Known hypersensitivity or contraindications to the study drug or its components;\n* Use of prohibited medications prior to screening and during the course of the study; History of drug abuse or drug dependence;\n* Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;\n* If female, is pregnant or lactating, or intends to become pregnant during the study period.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).\n\nThis study consists of two parts (Phase 1a and Phase 1b):\n\nPhase 1a (SAD) is a single-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, and PK of VVN432 Nasal Spray in healthy adult subjects.\n\nPhase 1b (MAD) is a multi-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, PK\u002FPD, and preliminary efficacy of VVN432 Nasal Spray in patients with chronic rhinosinusitis.",[28],"Chronic Rhinosinusitis (CRS)","RECRUITING","2025-11-20",{"date":32,"type":33},"2025-12-02","ACTUAL",{"date":35,"type":33},"2025-11-06",{"date":37,"type":22},"2026-11-30",{"name":39,"class":40},"VivaVision Biotech, Inc","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100603460","phase-3-a-phase-3-study-of-vvn461-ophthalmic-solution-for-noninfectious-anterior-uveitis-100603460","NCT07136805","A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","A Multi-center, Randomized, Single-masked, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 1.0% VVN461 Ophthalmic Solution in Patients With Non-infectious Anterior Uveitis","Inclusion Criteria:\n\n* At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive);\n* At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);\n* At screening, the ACC grade of the affected eye is 2+ or 3+ \\[SUN criteria\\];\n* At screening, the ACF grade of the affected eye is ≥1 \\[SUN criteria\\];\n\nExclusion Criteria:\n\n* At screening, the affected eye has an ACC grade of 4+ or hypopyon\n* Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening","70 Years",{"count":51,"type":22},152,[53],"PHASE3","This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China",[56],"Non-infectious Anterior Uveitis","NOT_YET_RECRUITING","2025-08-15",{"date":60,"type":33},"2025-08-22",{"date":62,"type":22},"2025-10-01",{"date":64,"type":22},"2027-04-30",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":41},"100543766","phase-3-study-of-5-vvn001-ophthalmic-solution-in-dry-eye-disease-100543766","NCT06360133","Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease","A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease","Inclusion Criteria:\n\n* Provided written informed consent prior to any study-related procedures.\n* Are between 30 and 80 years of age.\n* Have a history of dry eye disease in both eyes.\n* Have been using artificial tears within 30 days of the screening visit\n* Have an Eye dryness score ≥50 (0-100 point VAS)\n* Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm\u002F5 min.\n* Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).\n\nExclusion Criteria:\n\n* Have a known hypersensitivity or contraindication to the IP or components of IP.\n* Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.\n* Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.","30 Years","80 Years",{"count":76,"type":22},700,[53],"This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.",[80],"Dry Eye","2024-11-17",{"date":83,"type":33},"2024-11-20",{"date":85,"type":33},"2024-04-01",{"date":87,"type":22},"2026-03-31",{"name":39,"class":40},""]